TYZAVAN™ is the only FDA approved, ready-to-use, shelf stable at room temperature vancomycin premix injection available in seven strengths.
Company Background
Better health. Within reach. Every day.™
As a trusted partner and dependable source of high-quality medicines with more than 800+ products, our dedicated team at Hikma is always in reach when you need us. With over 29 manufacturing facilities, nine R&D centers and 9,500+ employees worldwide, we are deeply committed to providing a broad range of essential medicines that hospitals, physicians, and pharmacists need to treat their patients. Because for us, it’s not just business, its personal.
Product Overview
TYZAVAN™ is a glycopeptide antibacterial indicated in adults and pediatric patients (one month and older) for whom appropriate dosing with this formulation can be achieved for the treatment of the following infections:
- Septicemia
- Infective Endocarditis
- Skin and Skin Structure Infections
- Bone Infections
- Lower Respiratory Tract Infections
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN™ and other antibacterial drugs, TYZAVAN™ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy [TYZAVAN™ (vancomycin injection, USP), package insert].
What sets TYZAVAN™ apart:
- No compounding, thawing, or dilution required — ready-to-use, aseptically filled bags.
- Room temperature stability — 16-month shelf life, no refrigeration needed, and shelf-stable.
- Seven strengths (0.5g-2g) — supports flexible dosing according to patient’s need.
- Automated dispensing cabinet compatible — fits seamlessly into hospital workflows.
With sepsis diagnosed every 20 seconds in the U.S.2, and survival rates dropping significantly with delayed treatment3, TYZAVAN™ (vancomycin injection, USP) offers a practical solution to help hospitals respond faster and more efficiently.
